Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.

被引：4
|
作者：
Caffo, Orazio
Bria, Emilio
De Giorgi, Ugo
Tucci, Marcello
Galli, Luca
Fratino, Lucia
Rossetti, Sabrina
Iacovelli, Roberto
Lo Re, Giovanni
Mosillo, Claudia
Gasparro, Donatello
Guglielmini, Pamela Francesca
Damiani, Azzurra
Procopio, Giuseppe
De Lisi, Delia
Ruatta, Fiorella
Scagliarini, Sarah
Donini, Maddalena
Sperduti, Isabella
Basso, Umberto
机构：
[1] Santa Chiara Hosp, Med Oncol, Trento, Italy
[2] Univ Verona, Verona, Italy
[3] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[4] San Luigi Hosp, Orbassano, Italy
[5] Azienda Osped Univ Pisana, Pisa, Italy
[6] Natl Canc Ctr CRO, Aviano, Italy
[7] Ist Nazl Tumori Fdn G Pascale IRCCS, Div Med Oncol, Dept Uro Gynaecol Oncol, Naples, Italy
[8] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Verona, Italy
[9] Santa Maria Angeli Gen Hosp, Pordenone, Italy
[10] Sapienza Univ Rome, Policlin Umberto 1, Rome, Italy
[11] Azienda Osped Univ Parma, Parma, Italy
[12] SS Antonio & Biagio & Cesare Arrigo Gen Hosp, Oncol, Alessandria, Italy
[13] Azienda Osped Univ San Martino, Genoa, Italy
[14] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[15] Campus Bio Med Univ Rome, Dept Med Oncol, Rome, Italy
[16] Fdn Piemonte Oncol IRCCS, Med Oncol, Candiolo, Italy
[17] Cardarelli Hosp, Naples, Italy
[18] Osped Cremona, SC Oncol, Cremona, Italy
[19] Regina Elena Inst Canc Res, Biostat Unit, Rome, Italy
[20] Ist Oncol Veneto IOV IRCCS, Dept Clin & Expt Oncol, Med Oncol Unit, Padua, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5030
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
    Caffo, O.
    Biasco, E.
    Facchini, G.
    Fratino, L.
    Gasparro, D.
    Mosillo, C.
    Basso, U.
    Santini, D.
    Tucci, M.
    Ortega, C.
    Verderame, F.
    Scagliarini, S.
    Lo Re, G.
    Procopio, G.
    Fornarini, G.
    Campadelli, E.
    Sabbatini, R.
    Maines, F.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
    Caffo, O.
    Biasco, E.
    Facchini, G.
    Fratino, L.
    Gasparro, D.
    Mosillo, C.
    Maruzzo, M.
    Santini, D.
    Tucci, M.
    Ortega, C.
    Verderame, F.
    Scagliarini, S.
    Lo Re, G.
    Procopio, G.
    Fornarini, G.
    Campadelli, E.
    Sabbatini, R.
    Maines, F.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).
    Veccia, Antonello
    Caffo, Orazio
    Burgio, Salvatore Luca
    di Lorenzo, Giuseppe
    Ortega, Cinzia
    Scognamiglio, Florinda
    Mattioli, Rodolfo
    Mansueto, Giovanni
    Zustovich, Fable
    Aieta, Michele
    Facchini, Gaetano
    Procopio, Giuseppe
    D'Angelo, Alessandro
    Spizzo, Gilbert
    De Giorgi, Ugo
    De Placido, Sabino
    Ruatta, Fiorella
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.
    Caffo, Orazio
    Basso, Umberto
    Facchini, Gaetano
    Gasparro, Donatello
    Alesini, Daniele
    Tucci, Marcello
    Ortega, Cinzia
    Fratino, Lucia
    Campadelli, Enrico
    Lo Re, Giovanni
    Sabbatini, Roberto
    Procopio, Giuseppe
    Zucali, Paolo A.
    D'Angelo, Alessandro
    Donini, Maddalena
    Massari, Francesco
    Ratta, Raffaele
    Sava, Teodoro
    Messina, Caterina
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.
    Caffo, Orazio
    De Giorgi, Ugo
    Ferra, Francesco
    Donini, Maddalena
    Facchini, Gaetano
    Maruzzo, Marco
    Tucci, Marcello
    Conteduca, Vincenza
    Maines, Francesca
    Rossi, Lorena
    Veccia, Antonello
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] New agents (nas) in metastatic castration-resistant prostate cancer (mcrpc): is there a sequence better than the others?
    Maines, F.
    Caffo, O.
    Veccia, A.
    Galligioni, E.
    Trentin, C.
    Tortora, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 61 - 62
  • [7] Acitivity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.
    Caffo, Orazio
    De Giorgi, Ugo
    Facchini, Gaetano
    Fratino, Lucia
    Gasparro, Donatello
    Basso, Umberto
    Alesini, Daniele
    Tucci, Marcello
    Ortega, Cinzia
    Verderame, Francesco
    Procopio, Giuseppe
    Lo Re, Giovanni
    Campadelli, Enrico
    Omarini, Claudia
    Donini, Maddalena
    Morelli, Franco
    Zucali, Paolo A.
    Sartori, Donata
    Conteduca, Vincenza
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A pooled-analysis of the published studies.
    Maines, Francesca
    Caffo, Orazio
    Veccia, Antonello
    Bria, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [9] Patient Characteristics and Overall Survival (OS) in the Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) Community Setting
    Cheng, Wendy Y.
    Miao, Raymond
    Duh, Mei Sheng
    Vekeman, Francis
    Sung, Jennifer
    Gauthier-Loiselle, Marjolaine
    Fortier, Jonathan
    Dhawan, Ravinder
    Oh, William K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 557 - 558
  • [10] Clinical activity of enzalutamide pre- and post-docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Nadal, Rosa
    Zhang, Zhe
    Raheja, Hitesh
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345